Literature DB >> 8747411

Genetic polymorphism of CYP2C9 and its effect on warfarin maintenance dose requirement in patients undergoing anticoagulation therapy.

H Furuya1, P Fernandez-Salguero, W Gregory, H Taber, A Steward, F J Gonzalez, J R Idle.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 8747411     DOI： 10.1097/00008571-199512000-00008

Source DB:  PubMed          Journal:  Pharmacogenetics        ISSN： 0960-314X


× No keyword cloud information.
  52 in total

1.  Pharmacokinetics of tolbutamide in ethnic Chinese.

Authors:  A S Gross; S Bridge; G M Shenfield
Journal:  Br J Clin Pharmacol       Date:  1999-02       Impact factor: 4.335

2.  Practical Consideration of Genotype Imputation: Sample Size, Window Size, Reference Choice, and Untyped Rate.

Authors:  Boshao Zhang; Degui Zhi; Kui Zhang; Guimin Gao; Nita N Limdi; Nianjun Liu
Journal:  Stat Interface       Date:  2011       Impact factor: 0.582

Review 3.  Pharmacogenetics of target genes across the warfarin pharmacological pathway.

Authors:  Suman Lal; Srinivasa Rao Jada; Xiaoqiang Xiang; Wan-Teck Lim; Edmund J D Lee; Balram Chowbay
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

4.  Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study.

Authors:  John F Carlquist; Benjamin D Horne; Joseph B Muhlestein; Donald L Lappé; Bryant M Whiting; Matthew J Kolek; Jessica L Clarke; Brent C James; Jeffrey L Anderson
Journal:  J Thromb Thrombolysis       Date:  2006-12       Impact factor: 2.300

Review 5.  Comparative pharmacokinetics of vitamin K antagonists: warfarin, phenprocoumon and acenocoumarol.

Authors:  Mike Ufer
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

Review 6.  Effect of genetic polymorphisms in cytochrome p450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance.

Authors:  Julia Kirchheiner; Ivar Roots; Mark Goldammer; Bernd Rosenkranz; Jürgen Brockmöller
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

7.  Substrate proton to heme distances in CYP2C9 allelic variants and alterations by the heterotropic activator, dapsone.

Authors:  Matthew A Hummel; Peter M Gannett; Jarrett Aguilar; Timothy S Tracy
Journal:  Arch Biochem Biophys       Date:  2008-05-01       Impact factor: 4.013

8.  VKORC1-1639A allele influences warfarin maintenance dosage among Blacks receiving warfarin anticoagulation: a retrospective cohort study.

Authors:  Fatima Donia Mili; Tenecia Allen; Paula Weinstein Wadell; W Craig Hooper; Christine De Staercke; Christopher J Bean; Cathy Lally; Harland Austin; Nanette K Wenger
Journal:  Future Cardiol       Date:  2017-12-08

9.  Pharmacokinetics of diclofenac and inhibition of cyclooxygenases 1 and 2: no relationship to the CYP2C9 genetic polymorphism in humans.

Authors:  Julia Kirchheiner; Ingolf Meineke; Nadine Steinbach; Christian Meisel; Ivar Roots; Jürgen Brockmöller
Journal:  Br J Clin Pharmacol       Date:  2003-01       Impact factor: 4.335

Review 10.  Understanding the pharmacogenetic approach to warfarin dosing.

Authors:  Ingrid Glurich; James K Burmester; Michael D Caldwell
Journal:  Heart Fail Rev       Date:  2008-11-08       Impact factor: 4.214
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.